Hsp90α Is Suitable for Therapy Monitoring in Multiple Cancers

Background: Heat shock protein 90α (Hsp90α) is associated with the occurrence and development of cancer. Previous studies have shown that plasma Hsp90α protein has high sensitivity and specificity in the diagnosis of liver cancer and lung cancer. Although the study of the Hsp90α protein in cancer screening is more common, the application of the Hsp90α protein in diagnosis and monitoring of cancer is rare. Methods: : In this study, 370 cancer patients were enrolled from Nanyang Second People's Hospital (Henan, China). The pre- and post-treatment protein expression of Hsp90α were inspected and the data were analyzed. Results: : In our research, Hsp90α expression was lower in the T1 phase of lung cancer, esophageal cancer, and gastric cancer patients with prior treatment and higher in breast cancer patients. Apart from colorectal cancer, Hsp90α expression of different cancer types in the T4 phase was highest compared to T1 to T3 phase, and the expression Hsp90α protein increased with cancer progression. These results substantiated that Hsp90α protein expression was consistent with cancer progression overall, although the expression difference between tumor stages was not obvious. Hsp90α was detected in 54 lung cancer patients pre- and post-treatment, and the coincidence rate between the progression of disease and expression change in the Hsp90α protein was 79.63%. For further verification, some patients of them underwent long-term monitoring, and the coincidence rate was 75%. Conclusions: : Hsp90α was a potential biomarker for therapeutic monitoring of cancer prognosis, including lung cancer, esophageal cancer, gastric cancer and breast cancer.